Veradermics, Inc (MANE) is held by 3 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions, 1 fund adding, and 3 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $230.8M sold). Latest close $124.86 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 11, 2026 · Congress to Nov 16, 2026.
Deep Track Capital · Maverick Capital · Viking Global Investors — 3 tracked funds hold MANE. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 6 sales ($230.8M). Insider trading
Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Deep Track Capital | 3.58% | 2,000,000 | ADDED (+300.0%) Q3 filed Nov 16 |
| Maverick Capital | 0.86% | 789,980 | NEW Q3 filed Nov 16 |
| Viking Global Investors | 0.55% | 1,561,494 | TRIMMED (-7.6%) Q3 filed Nov 16 |
| Deerfield Management | — | — | EXITED |
| Paradigm Biocapital Advisors | — | — | EXITED |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -2.2% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 200 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 164 of 8,857 filers |
| Long-only filers among them | 164 |
| Change vs 2026 Q1 | +87 net · 161 entered · 74 exited |
| Shares reported, all filers | 33,940,197 |
| Reported value, all filers | $4.2B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Net income · FY2025 | $-70.0M |
| Total assets · FY2025 | $152.6M |
| Shares outstanding | 41,780,136 |
| Market cap (at latest close) | $5.2B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 6, 2026.
| Shares short · Oct 15, 2026 | 3,698,387 |
| Share of shares outstanding | 8.85% |
| Days to cover | 3.77 |
Shares short at recent settlements — Jul 31, 2026: 4.8M · Aug 14, 2026: 4.0M · Aug 31, 2026: 4.0M · Sep 15, 2026: 4.1M · Sep 30, 2026: 4.2M · Oct 15, 2026: 3.7M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 6, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 2 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 5 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 6, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 6 sales by 3 insiders ($230.8M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 11, 2026 | ENRIGHT PATRICK G | Sell | 250,000 | $150.38 | $37.6M | SEC filing | |
| Nov 11, 2026 | ENRIGHT PATRICK G | Sell | 250,000 | $150.38 | $37.6M | SEC filing | |
| Nov 11, 2026 | Longitude Capital Partners V, LLC | Sell | 250,000 | $150.38 | $37.6M | SEC filing | |
| Nov 11, 2026 | Longitude Capital Partners V, LLC | Sell | 250,000 | $150.38 | $37.6M | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | Averill Master Fund, Ltd. | Affiliate | 690,601 | $74.1M | Aug 19, 2026 | SEC filing |
| Aug 19, 2026 | Averill Madison Master Fund, Ltd. | Affiliate | 59,399 | $6.4M | Aug 19, 2026 | SEC filing |
| Aug 17, 2026 | Timothy Durso | Officer | 87,000 | $9.7M | Aug 17, 2026 | SEC filing |
| Aug 17, 2026 | Reid Alexander Waldman | CEO | 135,000 | $15.0M | Aug 17, 2026 | SEC filing |
| Aug 14, 2026 | John W. Childs 2013 Revocable Trust | Affiliate | 100,000 | $10.9M | Aug 12, 2026 | SEC filing |
| Aug 12, 2026 | AMZL, LP | Shareholder | 104,587 | $11.4M | Aug 12, 2026 | SEC filing |
| Aug 12, 2026 | SR One Capital Fund II Aggregator, LP | Shareholder | 217,162 | $23.7M | Aug 12, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Form | Price change since disclosure |
|---|---|---|
| Aug 21, 2026 | SCHEDULE 13D/A | +27.6% (close Aug 24, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Aug 24, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 21, 2026 | Montanova Capital, LLC | SC 13D/A | 3,718,970 | 8.8% | Aug 19, 2026 | SEC filing |
| Aug 14, 2026 | SR One Capital Management, LLC | SC 13D/A | 2,080,119 | 4.9% | Aug 12, 2026 | SEC filing |
| Aug 6, 2026 | FMR LLC | SC 13G | 3,193,181 | 7.6% | Jun 30, 2026 | SEC filing |
| May 15, 2026 | VIKING GLOBAL INVESTORS LP | SC 13G/A | 1,690,555 | 4.5% | Mar 31, 2026 | SEC filing |
| May 7, 2026 | Citadel Advisors LLC | SC 13G | 1,870,775 | 4.5% | Apr 30, 2026 | SEC filing |
| May 5, 2026 | Longitude Capital Partners V, LLC | SC 13D/A | 2,600,399 | 6.3% | May 1, 2026 | SEC filing |
| May 5, 2026 | Seven Fleet Master Fund LP | SC 13D | 80,000 | 0.2% | May 1, 2026 | SEC filing |
| May 5, 2026 | SUVRETTA CAPITAL MANAGEMENT, LLC | SC 13D/A | 4,172,121 | 9.9% | May 1, 2026 | SEC filing |
| Feb 12, 2026 | Longitude Capital Partners V, LLC | SC 13D | 2,600,399 | 7.0% | Feb 5, 2026 | SEC filing |
| Feb 12, 2026 | VIKING GLOBAL INVESTORS LP | SC 13G | 2,151,493 | 5.8% | Feb 5, 2026 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Financial Screens
· Net-Net (NCAV) — Market cap below net current asset value
Red Flags
· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10
· Excess Accruals (Sloan) — Sloan accruals ratio beyond ±25%
Key figures
· Net-Net (NCAV) — NCAV: $143.3M · Market cap: $107.2M · NCAV / market cap: 1.34
· Distress Risk (Altman Z″) — Z″-Score: -13.54 · Working capital / assets: 0.94 · Retained earnings / assets: -0.81 · EBIT / assets: -0.47 · Equity / liabilities: -13.22
· Excess Accruals (Sloan) — Accruals ratio: 78.9% · Net income: $-70.0M · Operating cash flow: $-71.6M · Investing cash flow: $-118.9M
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2026 Q1, ranked #9 of 50.
Also held by the tracked funds that hold MANE — ranked by lift, the co-holding pattern described in Methodology: Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT) · NOVARTIS AG (NVS).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
Filings audit: every filing lens on Veradermics, Inc (MANE), scored — GetCoattail Research.
| Filed | Items | Source |
|---|---|---|
| Nov 10, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Nov 9, 2026 | 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 19, 2026 | 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Merck & Co., Inc. (MRK) · Filings audit: every filing lens on Veradermics, Inc (MANE), scored · Practice timing on MANE
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.